JPWO2020207991A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020207991A5
JPWO2020207991A5 JP2021559754A JP2021559754A JPWO2020207991A5 JP WO2020207991 A5 JPWO2020207991 A5 JP WO2020207991A5 JP 2021559754 A JP2021559754 A JP 2021559754A JP 2021559754 A JP2021559754 A JP 2021559754A JP WO2020207991 A5 JPWO2020207991 A5 JP WO2020207991A5
Authority
JP
Japan
Prior art keywords
methyl
hexahydro
pyrazino
amino
carbonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021559754A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527588A (ja
JP7692838B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/059831 external-priority patent/WO2020207991A1/en
Publication of JP2022527588A publication Critical patent/JP2022527588A/ja
Publication of JPWO2020207991A5 publication Critical patent/JPWO2020207991A5/ja
Application granted granted Critical
Publication of JP7692838B2 publication Critical patent/JP7692838B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021559754A 2019-04-09 2020-04-07 自己免疫疾患の治療のためのヘキサヒドロ－１Ｈ－ピラジノ［１，２－ａ］ピラジン化合物 Active JP7692838B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/081900 2019-04-09
CN2019081900 2019-04-09
CNPCT/CN2019/121598 2019-11-28
CN2019121598 2019-11-28
CN2020078225 2020-03-06
CNPCT/CN2020/078225 2020-03-06
PCT/EP2020/059831 WO2020207991A1 (en) 2019-04-09 2020-04-07 Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease

Publications (3)

Publication Number Publication Date
JP2022527588A JP2022527588A (ja) 2022-06-02
JPWO2020207991A5 true JPWO2020207991A5 (enExample) 2023-04-10
JP7692838B2 JP7692838B2 (ja) 2025-06-16

Family

ID=70228042

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021559754A Active JP7692838B2 (ja) 2019-04-09 2020-04-07 自己免疫疾患の治療のためのヘキサヒドロ－１Ｈ－ピラジノ［１，２－ａ］ピラジン化合物

Country Status (19)

Country Link
US (1) US20220340597A1 (enExample)
EP (1) EP3953356B1 (enExample)
JP (1) JP7692838B2 (enExample)
KR (1) KR20210149163A (enExample)
CN (1) CN113710672B (enExample)
AU (1) AU2020272467A1 (enExample)
BR (1) BR112021020297A2 (enExample)
CA (1) CA3135129A1 (enExample)
CL (1) CL2021002621A1 (enExample)
CO (1) CO2021013166A2 (enExample)
CR (1) CR20210513A (enExample)
IL (1) IL286870A (enExample)
MA (1) MA55594A (enExample)
MX (1) MX2021012223A (enExample)
PE (1) PE20212178A1 (enExample)
PH (1) PH12021552533A1 (enExample)
SG (1) SG11202110401WA (enExample)
TW (1) TW202104230A (enExample)
WO (1) WO2020207991A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021084022A1 (en) * 2019-10-31 2021-05-06 F. Hoffmann-La Roche Ag Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
US20230002375A1 (en) * 2019-11-12 2023-01-05 Hoffmann-La Roche Inc. Hydropyrazino[1,2-b]isoquinoline compounds for the treatment of autoimmune disease
CN114728976B (zh) 2019-11-19 2024-08-16 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢-1H-吡咯并[1,2-a]吡嗪化合物
US12503471B2 (en) 2019-11-19 2025-12-23 Hoffmann-La Roche Inc. Triazatricycle compounds for the treatment of autoimmune disease
WO2021105117A1 (en) 2019-11-28 2021-06-03 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
CN114761406B (zh) * 2019-12-03 2024-04-19 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢吡啶并[1,2-a]吡嗪化合物
US20240317735A1 (en) * 2020-07-14 2024-09-26 Hoffmann-La Roche Inc. Hydroisoquinoline or hydronaphthyridine compounds for the treatment of autoimmune disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012097177A2 (en) * 2011-01-12 2012-07-19 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
NO2895477T3 (enExample) 2012-09-14 2018-03-31
CA2933466A1 (en) * 2013-12-13 2015-06-18 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors
SG11201804170RA (en) 2015-12-17 2018-06-28 Merck Patent Gmbh Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
CN112585134A (zh) * 2018-06-13 2021-03-30 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的吡啶基杂环基化合物
WO2020064792A1 (en) * 2018-09-27 2020-04-02 F. Hoffmann-La Roche Ag Heterocyclyl compounds for the treatment of autoimmune disease

Similar Documents

Publication Publication Date Title
CN105294683B (zh) Cdk类小分子抑制剂的化合物及其用途
AU2023201522B2 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JP7654071B2 (ja) 複素環スピロ化合物及び使用方法
CN105294681B (zh) Cdk类小分子抑制剂的化合物及其用途
AU2022265682A1 (en) 2-aminobenzothiazole compounds and methods of use thereof
SI3083625T1 (en) Pyrimidopyrimidinones, useful as Wee-1 kinase inhibitors
JP2025536259A (ja) 三環式化合物及びその使用
JPWO2020081848A5 (enExample)
JP2019535664A5 (enExample)
RU2019115115A (ru) Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7
TW202423440A (zh) Ｋｒａｓ ｇ１２ｃ突變蛋白的系鏈之雜環抑制劑及其用途
JPWO2019191092A5 (enExample)
JP2020510092A5 (enExample)
CN112313228A (zh) 用于治疗自身免疫性疾病的新型杂芳基杂环基化合物
KR20180061258A (ko) PI3Kβ 저해제로서의 퀴녹살린 및 피리도피라진 유도체
JPWO2020207991A5 (enExample)
JPWO2019197842A5 (enExample)
JPWO2019233941A5 (enExample)
CN111511361A (zh) 作为多激酶抑制剂的胺基碳酸盐及尿素化合物
RU2021131710A (ru) Соединения гексагидро-1h-пиразино[1,2-a]пиразина для лечения аутоиммунного заболевания
JPWO2022013307A5 (enExample)
JPWO2021087181A5 (enExample)
RU2020142969A (ru) СОЕДИНЕНИЯ ТЕТРАГИДРО-1Н-ПИРАЗИНО[2,1- a]ИЗОИНДОЛИЛХИНОЛИНА ДЛЯ ЛЕЧЕНИЯ АУТОИММУННОГО ЗАБОЛЕВАНИЯ
WO2025194057A1 (en) Macrocyclic compounds as modulators of kras and uses thereof
AU2023309768A1 (en) HETEROARYL DERIVATIVES AS DDRs INHIBITORS